Therapeutic outcomes and predictive factors of intradetrusor onabotulinumtoxinA for neurogenic detrusor overactivity (NDO) associated with spinal cord lesion.
Abstract
[PURPOSE] Intradetrusor onabotulinumtoxinA (Botox) is an established treatment for neurogenic detrusor overactivity (NDO), although predictors of success remain unclear. This study evaluated the therapeutic efficacy of Botox and identified predictors of response in patients with spinal cord lesion (SCL)-related NDO.
[METHODS] We retrospectively reviewed 167 patients with SCL-related NDO who received intradetrusor 200 U Botox at a single center between January 1, 2002, and December 31, 2024. Treatment response was classified using the Global Response Assessment (GRA) as excellent (GRA = 3), moderately improved (GRA = 2), mildly improved (GRA = 1), or no change (GRA = 0). Success was defined as GRA = 3 or 2. Baseline demographics, neurological level, and videourodynamic (VUDS) parameters, including detrusor pressure at maximum flow (Pdet), maximum flow rate, voided volume, post-void residual, voiding efficiency (VE), bladder outlet obstruction index (BOOI), and bladder contractility index (BCI), were analyzed as predictors.
[RESULTS] VUDS confirmed detrusor overactivity in 92.8%. Overall, 51.5% (86/167) achieved an excellent response, 43.1% (72/167) improved, and 5.4% (9/167) showed no change. Outcomes did not differ by neurological level (P = 0.665). Patients with successful outcomes had higher baseline P (41.9 ± 20.3 vs 22.9 ± 13.4 cmH₂O, P < 0.001), BOOI (33.2 ± 21.9 vs 12.7 ± 15.2, P < 0.001), and BCI (63.6 ± 33.0 vs 48.4 ± 27.9, P = 0.010), but lower VE (0.28 ± 0.31 vs 0.40 ± 0.35, P = 0.045). Logistic regression analysis showed that higher Pdet, BOOI, and BCI predicted treatment success, while higher VE predicted nonresponse. Sex distribution differed across GRA groups (P = 0.004), with more men in the failure group. Acute adverse events were similar among groups.
[CONCLUSIONS] Intradetrusor Botox produced good efficacy in SCL-related NDO. Higher baseline detrusor pressure, bladder contractility, and bladder outlet resistance predicted better outcomes, whereas greater VE was associated with nonresponse. Neurological level did not influence treatment success.
[METHODS] We retrospectively reviewed 167 patients with SCL-related NDO who received intradetrusor 200 U Botox at a single center between January 1, 2002, and December 31, 2024. Treatment response was classified using the Global Response Assessment (GRA) as excellent (GRA = 3), moderately improved (GRA = 2), mildly improved (GRA = 1), or no change (GRA = 0). Success was defined as GRA = 3 or 2. Baseline demographics, neurological level, and videourodynamic (VUDS) parameters, including detrusor pressure at maximum flow (Pdet), maximum flow rate, voided volume, post-void residual, voiding efficiency (VE), bladder outlet obstruction index (BOOI), and bladder contractility index (BCI), were analyzed as predictors.
[RESULTS] VUDS confirmed detrusor overactivity in 92.8%. Overall, 51.5% (86/167) achieved an excellent response, 43.1% (72/167) improved, and 5.4% (9/167) showed no change. Outcomes did not differ by neurological level (P = 0.665). Patients with successful outcomes had higher baseline P (41.9 ± 20.3 vs 22.9 ± 13.4 cmH₂O, P < 0.001), BOOI (33.2 ± 21.9 vs 12.7 ± 15.2, P < 0.001), and BCI (63.6 ± 33.0 vs 48.4 ± 27.9, P = 0.010), but lower VE (0.28 ± 0.31 vs 0.40 ± 0.35, P = 0.045). Logistic regression analysis showed that higher Pdet, BOOI, and BCI predicted treatment success, while higher VE predicted nonresponse. Sex distribution differed across GRA groups (P = 0.004), with more men in the failure group. Acute adverse events were similar among groups.
[CONCLUSIONS] Intradetrusor Botox produced good efficacy in SCL-related NDO. Higher baseline detrusor pressure, bladder contractility, and bladder outlet resistance predicted better outcomes, whereas greater VE was associated with nonresponse. Neurological level did not influence treatment success.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botox
|
보툴리눔독소 주사 | dict | 4 | |
| 해부 | detrusor
|
scispacy | 1 | ||
| 해부 | spinal cord
|
scispacy | 1 | ||
| 해부 | intradetrusor
|
scispacy | 1 | ||
| 해부 | GRA
→ Global Response Assessment
|
scispacy | 1 | ||
| 해부 | bladder
|
scispacy | 1 | ||
| 합병증 | detrusor pressure
|
scispacy | 1 | ||
| 합병증 | bladder outlet
|
scispacy | 1 | ||
| 약물 | intradetrusor onabotulinumtoxinA
|
scispacy | 1 | ||
| 약물 | NDO
→ neurogenic detrusor overactivity
|
scispacy | 1 | ||
| 약물 | 33.2
|
scispacy | 1 | ||
| 약물 | GRA
→ Global Response Assessment
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] Intradetrusor Botox
|
scispacy | 1 | ||
| 질환 | neurogenic detrusor overactivity
|
C0341736
Neurogenic detrusor overactivity
|
scispacy | 1 | |
| 질환 | bladder outlet obstruction
|
C0005694
Bladder neck obstruction
|
scispacy | 1 | |
| 질환 | detrusor overactivity
|
C0268849
Overactive Detrusor
|
scispacy | 1 | |
| 질환 | BOOI
→ bladder outlet obstruction index
|
C0005694
Bladder neck obstruction
|
scispacy | 1 | |
| 질환 | NDO
→ neurogenic detrusor overactivity
|
scispacy | 1 | ||
| 질환 | bladder outlet
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | men
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.